Comparable survival outcome of metastatic colorectal cancer in Indigenous and non-Indigenous patients: retrospective analysis of the South Australian metastatic colorectal cancer registry Tomita, Yoko; Karapetis, Christos S; Roder, David; ...

User activity

Share to:
Tomita, Yoko ; Karapetis, Christos S ; Roder, David ; Beeke, Carol ; Hocking, Christopher ; Roy, Amitesh C ; Townsend, Amanda R ; Padbury, Robert ; Maddern, Guy ; Price, Timothy J
Appears In
Australian Journal of Rural Health
colorectal neoplasm indigenous population survival therapeutics treatment outcome; Colorectal cancer -- Analysis; Histochemistry -- Analysis
To purchase or authenticate to the full-text of this article, please visit this link: Byline: Yoko Tomita, Christos S. Karapetis, David Roder, Carol Beeke, Christopher Hocking, Amitesh C. Roy, Amanda R. Townsend, Rob Padbury, Guy Maddern, Timothy J. Price Keywords: colorectal neoplasm; indigenous population; survival; therapeutics; treatment outcome Abstract Objective This study aims to investigate disparities in demographics, disease characteristics, treatment and overall survival between South Australian (SA) Indigenous and non-Indigenous patients with metastatic colorectal cancer (mCRC). Design This employs a retrospective population study using the SA mCRC registry. Setting The SA mCRC registry identifies mCRC patients from hospital encounters, histopathology reports, medical oncology letters, clinician notification, attendances at multidisciplinary meetings and death audits by the SA Cancer Registry. Participants A total of 2865 adult mCRC patients including 14 Indigenous patients were identified through the SA mCRC registry between February 2006 and August 2013. Patients were linked to the SA Cancer Registry to obtain Indigenous status. Main outcome measures Demographic, disease and treatment characteristics were compared using Chi-squared test and t-test; while overall survival defined as time to any cause of death was analysed using Cox regression. Results No difference was observed for clinical characteristics, except for a higher proportion of Indigenous patients receiving chemotherapy (85.7% versus 58.5%; P=0.04). The rate of liver surgery was similar across the two groups (21.0% versus 15.1%; P=0.40). The median overall survivals were equivalent (11.9 months versus 15.1 months; hazard ratio =1.00; 95% confidence interval for hazard ratio, 0.54-1.86). Conclusions Clinical characteristics and survival outcomes were similar between Indigenous and non-Indigenous patients captured on the SA mCRC registry, and outcome of those who have an access to comprehensive cancer care appeared independent of Indigenous status and in line with large clinical trials. Underestimation of Indigenous cases due to their lower utilisation of cancer service could not be excluded and ultimately the accurate reporting of these patients is crucial. Article Note: The manuscript was prepared by the lead author and this was reviewed and agreed upon by the remaining authors.
Work ID

2 editions of this work

Find a specific edition
Thumbnail [View as table] [View as grid] Title, Author, Edition Date Language Format Libraries

User activity

e.g. test cricket, Perth (WA), "Parkes, Henry"

Separate different tags with a comma. To include a comma in your tag, surround the tag with double quotes.

Be the first to add a tag for this work

Be the first to add this to a list

Comments and reviews

What are comments? Add a comment

No user comments or reviews for this work

Add a comment

Show comments and reviews from Amazon users